|Results 1-1||<< Back|
Mentions: Lastly, we checked if GPC3 could activate the downstream mitogenic pathway. In western blot analysis, the levels of total ERK in the parental NIH3T3 cells, 12-O-tetradecanoylphorbol 13-acetate treatment HEK293 cells or GPC3 expression NIH3T3 cells were equal (Figure 5A). 12-O-tetradecanoylphorbol 13-acetate induced prominent ERK phosphorylation in HEK293 cells (Figure 5A, lane 2). Phospho-ERK was barely visible in the parental NIH3T3 cells, but was abundant in GPC3-expressing cell lines GPC3-60 and GPC3-65 (Figure 5A, lanes 3 and 4). In the GPC3-high-expressing HuH-7 cells, ERK phosphorylation was high, but phospho-ERK decreased when GPC3 was knocked down by gpc3 shRNA (Figure 5B). In the GPC3-low-expressing PLC-PRF-5 and HA22T/VGH cells, stable expression of GPC3 caused the elevation of phospho-ERK, but mutants RR → AA or P25-29A had much less effects (Figure 5C and D). Serum starvation for the HA22T/VGH cells was done in 0.5% serum because in 0% serum no ERK phosphorylation could be seen. This could be due to the low IGF-II expression in HA22T/VGH cells (Figure 3A).
Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway
Bottom Line: Also, GPC3 knockdown in HCC cells decreased the phosphorylation of both IGF-1R and ERK.Therefore, GPC3 confers oncogenecity through the interaction between IGF-II and its receptor, and the subsequent activation of the IGF-signaling pathway.This data are novel to the current understanding of the role of GPC3 in HCC and will be important in future developments of cancer therapy.
Affiliation: Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Glypican-3 (gpc3) is the gene responsible for Simpson-Golabi-Behmel overgrowth syndrome. Previously, we have shown that GPC3 is overexpressed in hepatocellular carcinoma (HCC). In this study, we demonstrated the mechanisms for GPC3-mediated oncogenesis. Firstly, GPC3 overexpression in NIH3T3 cells gave to cancer cell phenotypes including growing in serum-free medium and forming colonies in soft agar, or on the other way, GPC3 knockdown in HuH-7 cells decreased oncogenecity. We further demonstrated that GPC3 bound specifically through its N-terminal proline-rich region to both Insulin-like growth factor (IGF)-II and IGF-1R. GPC3 stimulated the phosphorylation of IGF-1R and the downstream signaling molecule extracellular signal-regulated kinase (ERK) in an IGF-II-dependent way. Also, GPC3 knockdown in HCC cells decreased the phosphorylation of both IGF-1R and ERK. Therefore, GPC3 confers oncogenecity through the interaction between IGF-II and its receptor, and the subsequent activation of the IGF-signaling pathway. This data are novel to the current understanding of the role of GPC3 in HCC and will be important in future developments of cancer therapy.
View Similar Images In: Results Collection View Article: Medline Plus Pubmed Central PubMed Show All Figures